|Articles|July 31, 2017
LabCorp to Acquire Chiltern for Approximately $1.2 Billion
Advertisement
LabCorp-global life sciences company-and specialty CRO, Chiltern, announced that LabCorp will acquire Chiltern in an all-cash transaction for approximately $1.2 billion. Following the completion of the transaction, Chiltern will become part of LabCorp’s Covance segment.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Takeda’s Phase III TIDES Trial Confirms Long-Term Efficacy and Safety of Qdenga Dengue Vaccine
2
Streamlining Clinical Data to Reduce Site and Participant Burden
3
Utilizing Tech Tools to Accelerate Drug Development
4
ACT Brief: Lilly Seeks FDA Priority Review for Oral GLP-1 as Bispecific Antibody Trials Redefine Ethical Standards
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
